Literature DB >> 22955109

The role of TGF-β and myofibroblasts in the arteritis of Kawasaki disease.

Chisato Shimizu1, Toshiaki Oharaseki, Kei Takahashi, Aubri Kottek, Alessandra Franco, Jane C Burns.   

Abstract

Inflammation of medium-sized, muscular arteries and coronary artery aneurysms are hallmarks of Kawasaki disease (KD), an acute, self-limited vasculitis of children. We previously reported that genetic variation in transforming growth factor (TGF)-β pathway genes influences both susceptibility to KD and coronary artery aneurysm (CAA) formation. TGF-β signaling has been implicated in the generation of myofibroblasts that influence collagen lattice contraction, antigen presentation, and recruitment of inflammatory cells as well as the generation of regulatory T-cells (Tregs). These processes could be involved in aneurysm formation and recovery in KD. Coronary artery tissues from 8 KD patient autopsies were stained to detect proteins in the TGF-β pathway, to characterize myofibroblasts, and to detect Tregs. Expression of proteins in the TGF-β pathway was noted in infiltrating mononuclear cells and spindle-shaped cells in the thickened intima and adventitia. Coronary arteries from an infant who died on Illness Day 12 showed α-smooth muscle actin (SMA)-positive, smoothelin-negative myofibroblasts in the thickened intima that co-expressed IL-17 and IL-6. CD8+ T-cells expressing HLA-DR+ (marker of activation and proliferation) were detected in the aneurysmal arterial wall. Forkhead box P3 (FOXP3), whose expression is essential for Tregs, was also detected in the nucleus of infiltrating mononuclear cells, suggesting a role for Tregs in recovery from KD arteritis.TGF-β may contribute to aneurysm formation by promoting the generation of myofibroblasts that mediate damage to the arterial wall through recruitment of pro-inflammatory cells. This multi-functional growth factor may also be involved in the induction of Tregs in KD.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22955109      PMCID: PMC3518690          DOI: 10.1016/j.humpath.2012.05.004

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  34 in total

1.  Mechanisms of neointima formation and remodeling in the porcine coronary artery.

Authors:  T Christen; V Verin; M Bochaton-Piallat; Y Popowski; F Ramaekers; P Debruyne; E Camenzind; G van Eys; G Gabbiani
Journal:  Circulation       Date:  2001-02-13       Impact factor: 29.690

2.  Smad3 signaling critically regulates fibroblast phenotype and function in healing myocardial infarction.

Authors:  Marcin Dobaczewski; Marcin Bujak; Na Li; Carlos Gonzalez-Quesada; Leonardo H Mendoza; Xiao-Fan Wang; Nikolaos G Frangogiannis
Journal:  Circ Res       Date:  2010-06-03       Impact factor: 17.367

3.  Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association.

Authors:  Jane W Newburger; Masato Takahashi; Michael A Gerber; Michael H Gewitz; Lloyd Y Tani; Jane C Burns; Stanford T Shulman; Ann F Bolger; Patricia Ferrieri; Robert S Baltimore; Walter R Wilson; Larry M Baddour; Matthew E Levison; Thomas J Pallasch; Donald A Falace; Kathryn A Taubert
Journal:  Circulation       Date:  2004-10-26       Impact factor: 29.690

4.  Immunohistochemical study of apparently intact coronary artery in a child after Kawasaki disease.

Authors:  Atsuko Suzuki; Sachiko Miyagawa-Tomita; Keiko Komatsu; Makoto Nakazawa; Takashi Fukaya; Kunizou Baba; Chikao Yutani
Journal:  Pediatr Int       Date:  2004-10       Impact factor: 1.524

5.  A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome.

Authors:  J W Newburger; M Takahashi; A S Beiser; J C Burns; J Bastian; K J Chung; S D Colan; C E Duffy; D R Fulton; M P Glode
Journal:  N Engl J Med       Date:  1991-06-06       Impact factor: 91.245

6.  Class II major histocompatibility antigen expression on coronary arterial endothelium in a patient with Kawasaki disease.

Authors:  M Terai; Y Kohno; M Namba; T Umemiya; K Niwa; H Nakajima; A Mikata
Journal:  Hum Pathol       Date:  1990-02       Impact factor: 3.466

Review 7.  Kawasaki syndrome.

Authors:  Jane C Burns; Mary P Glodé
Journal:  Lancet       Date:  2004 Aug 7-13       Impact factor: 79.321

8.  Myofibroblasts from diverse pathologic settings are heterogeneous in their content of actin isoforms and intermediate filament proteins.

Authors:  O Skalli; W Schürch; T Seemayer; R Lagacé; D Montandon; B Pittet; G Gabbiani
Journal:  Lab Invest       Date:  1989-02       Impact factor: 5.662

9.  Histopathological features of murine systemic vasculitis caused by Candida albicans extract--an animal model of Kawasaki disease.

Authors:  K Takahashi; T Oharaseki; M Wakayama; Y Yokouchi; S Naoe; H Murata
Journal:  Inflamm Res       Date:  2004-01-26       Impact factor: 4.575

10.  Superantigenic activity is responsible for induction of coronary arteritis in mice: an animal model of Kawasaki disease.

Authors:  Trang T Duong; Earl D Silverman; Martindale V Bissessar; Rae S M Yeung
Journal:  Int Immunol       Date:  2003-01       Impact factor: 4.823

View more
  32 in total

1.  Association between SRC-1 gene polymorphisms and coronary artery aneurysms formation in Taiwanese children with Kawasaki disease.

Authors:  Yng-Tay Chen; Wen-Lin Liao; Ying-Ju Lin; Shih-Yin Chen; Fuu-Jen Tsai
Journal:  J Clin Lab Anal       Date:  2014-03-20       Impact factor: 2.352

2.  miR-483 Targeting of CTGF Suppresses Endothelial-to-Mesenchymal Transition: Therapeutic Implications in Kawasaki Disease.

Authors:  Ming He; Zhen Chen; Marcy Martin; Jin Zhang; Panjamaporn Sangwung; Brian Woo; Adriana H Tremoulet; Chisato Shimizu; Mukesh K Jain; Jane C Burns; John Y-J Shyy
Journal:  Circ Res       Date:  2016-12-06       Impact factor: 17.367

3.  Urotensin 2 in Kawasaki disease pathogenesis.

Authors:  Cassidy Y Huang; Jane C Burns; Chisato Shimizu
Journal:  Pediatr Res       Date:  2017-08-16       Impact factor: 3.756

4.  Phase I/IIa Trial of Atorvastatin in Patients with Acute Kawasaki Disease with Coronary Artery Aneurysm.

Authors:  Adriana H Tremoulet; Sonia Jain; Pei-Ni Jone; Brookie M Best; Elizabeth H Duxbury; Alessandra Franco; Beth Printz; Samuel R Dominguez; Heather Heizer; Marsha S Anderson; Mary P Glodé; Feng He; Robert L Padilla; Chisato Shimizu; Emelia Bainto; Joan Pancheri; Harvey J Cohen; John C Whitin; Jane C Burns
Journal:  J Pediatr       Date:  2019-09-24       Impact factor: 4.406

Review 5.  Review: Found in Translation: International Initiatives Pursuing Interleukin-1 Blockade for Treatment of Acute Kawasaki Disease.

Authors:  Jane C Burns; Isabelle Koné-Paut; Taco Kuijpers; Chisato Shimizu; Adriana Tremoulet; Moshe Arditi
Journal:  Arthritis Rheumatol       Date:  2017-02       Impact factor: 10.995

6.  Genetics insights into the pathogenesis of Kawasaki disease.

Authors:  Jane C Burns; Jane W Newburger
Journal:  Circ Cardiovasc Genet       Date:  2012-06

7.  Cardiovascular pathology in 2 young adults with sudden, unexpected death due to coronary aneurysms from Kawasaki disease in childhood.

Authors:  Chisato Shimizu; Alka Sood; Hubert D Lau; Toshiaki Oharaseki; Kei Takahashi; Henry F Krous; Steven Campman; Jane C Burns
Journal:  Cardiovasc Pathol       Date:  2015-02-24       Impact factor: 2.185

Review 8.  The immunomodulatory effects of intravenous immunoglobulin therapy in Kawasaki disease.

Authors:  Jane C Burns; Alessandra Franco
Journal:  Expert Rev Clin Immunol       Date:  2015       Impact factor: 4.473

9.  Evaluating a novel treatment for coronary artery inflammation in acute Kawasaki disease: A Phase I/IIa trial of atorvastatin.

Authors:  Adriana H Tremoulet; Sonia Jain; Jane C Burns
Journal:  Expert Opin Orphan Drugs       Date:  2015-07-13       Impact factor: 0.694

Review 10.  Adjunctive therapies in Kawasaki disease.

Authors:  Adriana H Tremoulet
Journal:  Int J Rheum Dis       Date:  2017-10-27       Impact factor: 2.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.